Neural Basis of Decision-Making Deficits in Traumatic Brain Injury
- Conditions
- Traumatic Brain Injury
- Interventions
- Device: tDCSDrug: [11C] Raclopride
- Registration Number
- NCT02169310
- Brief Summary
Background:
People with a traumatic brain injury (TBI) can have trouble making the best possible decisions. Researchers want to learn more about the parts of the brain that control decision making. They also want to know how these are different between people. This may help predict how people make decisions after TBI.
Objective:
To learn more about which parts of the brain are involved in making decisions and how decisions may be hurt after TBI.
Eligibility:
Adults age 18 to 60.
Design:
Participants will be screened with medical history and physical exam. They will also take memory, attention, concentration, and thinking tests.
Participants will do up to 2 experiments.
For Experiment 1, participants may have 3 scans:
PET: a chemical is injected through a thin tube into an arm vein. Participants lie on a bed that slides in and out of the scanner.
MRI: a strong magnetic field and radio waves take pictures of the brain. Participants lie on a table that slides in and out of a metal cylinder. It makes loud knocking noises. Participants will get earplugs. They might be asked to do a task. A coil will be placed over the head.
MEG: a cone with magnetic field detectors is lowered onto participants head.
After the scans, participants will perform a decision-making task.
For Experiment 2, participants will perform a decision-making task before and after receiving transcranial direct current stimulation (tDCS).
tDCS: wet electrode sponges are placed over participants' scalp and forehead. A current passes between the electrodes. It stimulating the brain.
Participants will return 24-48 hours later to repeat the decision-making task.
...
- Detailed Description
Study Description:
Deficits in decision-making are commonly found in individuals after traumatic brain injury (TBI) and can have a severe negative impact on quality of life. Converging evidence from both animal model and human studies suggest that decision-making deficits are linked with abnormal mesocorticolimbic network structure and function, and could potentially be mitigated through interventions that improve function within these neuronal circuits.
Objectives:
1. Quantify differences in performance on a decision-making task between TBI patients and healthy volunteers;
2. Determine whether baseline features of mesocorticolimbic network structure and function predict subsequent decision-making performance in both TBI patients and healthy volunteers; and
3. Determine if facilitatory transcranial direct current stimulation (tDCS) applied over the dorsolateral prefrontal cortex (dlPFC), a mesocorticolimbic network region crucially involved in decision-making, improves decision-making after TBI.
Endpoints:
Primary Endpoint: The primary outcome measure for both Experiment 1 and 2 is performance in a computerized decision-making task.
Secondary Endpoints: Secondary outcome measures will include quantitative estimates of structural and functional mesocorticolimbic network features, including MRI-based structural and functional connectivity, MEG-based functional connectivity, baseline dlPFC GABA concentration measured with magnetic resonance spectroscopy (MRS) imaging, dopamine D2 receptor binding potential within mesocorticolimbic subcortical nuclei measured with \[11C\]raclopride PET (Experiment 1). Multimodal data fusion modeling will be used to explore the predictive relationship between baseline mesocorticolimbic network features and decision-making task performance within a unified state-space framework (Experiment 1), as well as the ability of these network features to predict inter-individual differences in the effects of tDCS on decision-making task performance (Experiment 2).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 [11C] Raclopride up to 40 adult TBI patients between the ages of 18 and 60 2 tDCS up to 40 adult healthy volunteers between the ages of 18 and 60 1 tDCS up to 40 adult TBI patients between the ages of 18 and 60
- Primary Outcome Measures
Name Time Method The primary objective of this protocol is to: quantify differences in performance on a decision-making task between TBI patients and healthy volunteers. Participation may be completed over the course of a week, or longer depending on participant s schedule and testing availability. Typically, individuals complete the full study with 4-7 days. The primary outcome measure for both Experiment 1 and 2 is performance in a computerized decision-making task.
- Secondary Outcome Measures
Name Time Method The secondary objectives of this protocol are to: determine whether baseline features of mesocorticolimbic network structure and function predict subsequent decision-making performance in both TBI patients and healthy volunteers; and determine i... Participation may be completed over the course of a week, or longer depending on participant s schedule and testing availability. Typically, individuals complete the full study with 4-7 days. Secondary outcome measures will include quantitative estimates of structural and functional mesocorticolimbic network features, including MRI-based structural and functional connectivity, MEG-based functional dynamics, baseline dlPFC GABA concentration measured with magnetic resonance spectroscopy (MRS) imaging, dopamine D2 receptor binding potential within mesocorticolimbic subcortical nuclei measured with \[11C\]raclopride PET (Experiment 1). Multimodal data fusion modeling will be used to explore the predictive relationship between baseline mesocorticolimbic network states and decision-making performance within a unified state-space framework (Experiment 1), as well as the ability of these network states to predict inter-individual differences in the effects of tDCS on decision-making performance (Experiment 2).
Trial Locations
- Locations (1)
National Institutes of Health Clinical Center
🇺🇸Bethesda, Maryland, United States